Avalglucosidase alfa vs alglucosidase alfaChange from baseline in 6MWT (metres) · adults with LOPD1 finding from 1 reviewEnzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 100 participantsModerate
Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placeboChange from baseline in 6MWT (metres) · 13 people with LOPD1 finding from 1 reviewEnzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 5 participantsVery low
Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placeboChange from baseline in 6MWT (metres) · 13 people with LOPD1 finding from 1 reviewEnzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 10 participantsVery low
Alglucosidase alfa vs placeboChange from baseline in 6MWT (metres) · 90 people with LOPD1 finding from 1 reviewEnzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 90 participantsModerate
VAL‐1221 vs alglucosidase alfaChange from baseline in 6MWT (metres) · adults with LOPD1 finding from 1 reviewEnzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 12 participantsVery low
Cipaglucosidase plus miglustat vs alglucosidase alfa plus placeboChange from baseline in 6MWT (metres) · adults with LOPD1 finding from 1 reviewEnzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 117 participantsLow